InVitae (NVTA) Cut to Strong Sell at ValuEngine
ValuEngine lowered shares of InVitae (NYSE:NVTA) from a sell rating to a strong sell rating in a report released on Friday morning.
NVTA has been the topic of several other research reports. Zacks Investment Research downgraded InVitae from a hold rating to a sell rating in a research note on Thursday, January 4th. BidaskClub downgraded InVitae from a hold rating to a sell rating in a research note on Thursday, November 2nd. Benchmark cut their target price on InVitae from $16.00 to $11.00 and set a buy rating for the company in a research report on Tuesday, January 16th. Leerink Swann cut their target price on InVitae from $12.00 to $10.00 and set an outperform rating for the company in a research report on Tuesday, January 16th. Finally, Ladenburg Thalmann Financial Services began coverage on InVitae in a research report on Friday, January 5th. They set a buy rating and a $15.00 target price for the company. Three investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $12.40.
InVitae (NYSE:NVTA) opened at $6.52 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.61 and a quick ratio of 2.61. InVitae has a 12 month low of $3.55 and a 12 month high of $10.41. The company has a market capitalization of $345.20, a PE ratio of -2.55 and a beta of 0.81.
Large investors have recently added to or reduced their stakes in the stock. Lakeview Capital Partners LLC purchased a new stake in shares of InVitae during the third quarter worth about $117,000. Gabelli Funds LLC purchased a new stake in shares of InVitae during the third quarter worth about $131,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of InVitae during the third quarter worth about $133,000. CAPROCK Group Inc. purchased a new stake in shares of InVitae during the third quarter worth about $139,000. Finally, Voya Investment Management LLC grew its position in shares of InVitae by 51.2% during the second quarter. Voya Investment Management LLC now owns 16,936 shares of the medical research company’s stock worth $162,000 after purchasing an additional 5,733 shares in the last quarter. Hedge funds and other institutional investors own 64.89% of the company’s stock.
InVitae Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.